Factor products
Cassie A. Barton, Jesse Bierman · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2019
Cited by 0 works. doi:10.1002/jac5.1069
Authors
References
- Antithrombotic Therapy for VTE Disease
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
- Guidelines for the management of hemophilia
- Idarucizumab for Dabigatran Reversal
- Evidence-Based Management of Anticoagulant Therapy
- The Hemophilias — From Royal Genes to Gene Therapy
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors